Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte precursor cell | 11 studies | 28% ± 13% | |
| type II pneumocyte | 10 studies | 31% ± 12% | |
| fibroblast | 10 studies | 25% ± 6% | |
| neuron | 9 studies | 36% ± 16% | |
| glutamatergic neuron | 7 studies | 44% ± 25% | |
| interneuron | 7 studies | 39% ± 20% | |
| GABAergic neuron | 7 studies | 47% ± 19% | |
| oligodendrocyte | 7 studies | 22% ± 6% | |
| connective tissue cell | 6 studies | 30% ± 12% | |
| pericyte | 6 studies | 21% ± 8% | |
| smooth muscle cell | 6 studies | 19% ± 3% | |
| basal cell | 6 studies | 31% ± 15% | |
| astrocyte | 6 studies | 22% ± 7% | |
| endothelial cell | 5 studies | 28% ± 12% | |
| epithelial cell | 5 studies | 31% ± 18% | |
| type I pneumocyte | 4 studies | 20% ± 6% | |
| myofibroblast cell | 4 studies | 24% ± 4% | |
| pancreatic A cell | 3 studies | 41% ± 18% | |
| progenitor cell | 3 studies | 19% ± 3% | |
| GABAergic interneuron | 3 studies | 22% ± 3% | |
| retinal ganglion cell | 3 studies | 46% ± 22% | |
| amacrine cell | 3 studies | 37% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 2368.00 | 244 / 245 | 100% | 64.70 | 501 / 502 |
| brain | 100% | 3120.14 | 2633 / 2642 | 100% | 107.86 | 702 / 705 |
| adrenal gland | 100% | 21110.51 | 258 / 258 | 99% | 114.28 | 227 / 230 |
| thymus | 100% | 1654.67 | 650 / 653 | 96% | 33.38 | 578 / 605 |
| skin | 100% | 3968.02 | 1805 / 1809 | 91% | 46.00 | 428 / 472 |
| breast | 100% | 1315.39 | 457 / 459 | 90% | 35.02 | 1006 / 1118 |
| lung | 97% | 2208.73 | 559 / 578 | 90% | 57.99 | 1041 / 1155 |
| esophagus | 100% | 2254.28 | 1444 / 1445 | 84% | 47.88 | 153 / 183 |
| kidney | 98% | 1205.64 | 87 / 89 | 85% | 29.61 | 765 / 901 |
| pancreas | 99% | 1290.19 | 326 / 328 | 80% | 18.73 | 143 / 178 |
| ovary | 100% | 2645.37 | 180 / 180 | 74% | 19.02 | 318 / 430 |
| stomach | 100% | 2053.11 | 359 / 359 | 67% | 16.15 | 191 / 286 |
| uterus | 100% | 1762.76 | 170 / 170 | 67% | 31.86 | 306 / 459 |
| intestine | 97% | 1334.75 | 938 / 966 | 69% | 15.20 | 361 / 527 |
| bladder | 100% | 1398.62 | 21 / 21 | 62% | 23.09 | 312 / 504 |
| liver | 65% | 506.99 | 147 / 226 | 83% | 35.55 | 337 / 406 |
| eye | 0% | 0 | 0 / 0 | 100% | 115.35 | 80 / 80 |
| ureter | 0% | 0 | 0 / 0 | 100% | 49.72 | 1 / 1 |
| blood vessel | 99% | 1555.45 | 1322 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 98% | 1232.21 | 237 / 241 | 0% | 0 | 0 / 0 |
| adipose | 98% | 1159.48 | 1183 / 1204 | 0% | 0 | 0 / 0 |
| heart | 80% | 702.05 | 685 / 861 | 0% | 0 | 0 / 0 |
| muscle | 76% | 629.04 | 609 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 76% | 35.82 | 34 / 45 |
| peripheral blood | 1% | 8.05 | 10 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0006749 | Biological process | glutathione metabolic process |
| GO_0005829 | Cellular component | cytosol |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0004364 | Molecular function | glutathione transferase activity |
| Gene name | GSTA4 |
| Protein name | Glutathione S-transferase A4 (EC 2.5.1.18) (GST class-alpha member 4) (Glutathione S-transferase A4-4) Glutathione S-transferase alpha 4 |
| Synonyms | |
| Description | FUNCTION: Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. This isozyme has a high catalytic efficiency with 4-hydroxyalkenals such as 4-hydroxynonenal (4-HNE). . |
| Accessions | ENST00000370963.9 [O15217-1] O15217 ENST00000370960.5 [O15217-2] Q5JW88 ENST00000370959.1 [O15217-1] ENST00000457564.1 |